Affiliation:
1. From the Department of Adult Oncology, Dana-Farber Cancer Institute and the Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; the Department of Health Policy and Management, Harvard School of Public Health, Boston, MA; and Fred Hutchinson Cancer Research Center, Seattle, WA.
Abstract
Abstract
Unrelated donor transplantation prolongs survival in some patients with chronic myelogenous leukemia (CML) in chronic phase. However, there are growing concerns about the intensive resources required for this procedure given health care budget constraints. To address this issue, we conducted a study of the costs and cost-effectiveness of unrelated donor transplantation for chronic phase CML. The costs of transplantation were derived from 157 patients from the Brigham and Women’s Hospital (BWH) and the Fred Hutchinson Cancer Research Center (FHCRC). Estimates of the effectiveness of transplantation were taken from our previous work using data from the International Bone Marrow Transplant Registry and the National Marrow Donor Program. The median cost of the first 6 months of care including donor identification, marrow collection, patient hospitalization for transplantation and all outpatient medications and readmissions through 6 months postmarrow infusion was $178,500 (range, $85,000 to $462,400) and the mean was $196,200. Mean costs for patients surviving beyond 6 months posttransplant were significantly lower than for patients dying within that period ($189,700 v $211,000, respectively,P = .03). Posttransplant follow-up costs were high for months 6 to 18, then decreased. The incremental cost-effectiveness of transplantation within 1 year of diagnosis versus -interferon therapy without transplant in the base case of a 35-year-old patient was $51,800/quality-adjusted life year (QALY) gained. Sensitivity analysis showed that most ratios were between $50,000 to $100,000/QALY or within the intermediate zone of acceptable cost-effectiveness ratios.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference30 articles.
1. Cancer Statistics, 1997.;Parker;CA Cancer J Clin,1997
2. Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries.;Silberman;N Engl J Med,1994
3. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years.;Marks;Ann Intern Med,1993
4. Allogeneic bone marrow transplantation for chronic myeloid leukemia.;Gratwohl;Bone Marrow Transplant,1996
5. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.;Laupacis;Can Med Assoc J,1992
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献